Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2023

Genmab — Januar 2023

Planlagt Fastgjort Låst Flyttet Genmab
644 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bibob
    wrote on sidst redigeret af
    #74

    God morgen. 🙂

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Stroka
      wrote on sidst redigeret af
      #75

      God morgen 🙂

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #76

        JNJ yesterday very positive on Genmab products again; biggest area of growth is MM portfolio; biggest disconnect wih the market is that these drugs do not cannibalise each other but create the treatment paradigm that is different by combining + sequencing these different medicines

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #77

          Mariposa/ Rybrevant ; runs through 2024, but potential interim analysis 2023; large market, very large opportunity for growth

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #78

            This feedback, coupled with positive assessment of Briuvi from KOLs, suggests that TG Therapeutics has a competitive product in its hands, though it simultaneously places further emphasis on the key outstanding question of whether a company of its size and relative commercial experience can maximise this opportunity. KOLs have raised the same issue and speculated that Briuvi could become the subject of a co-marketing agreement or perhaps even trigger a larger company to acquire TG Therapeutics.

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #79

              Just a moment...

              favicon

              (firstwordpharma.com)

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #80

                Nice comments EL

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #81

                  https://investor.seagen.com/events-and-presentations/default.aspx
                  Seagen JPM presentation

                  1 Reply Last reply
                  0
                  • StockBullS Offline
                    StockBullS Offline
                    StockBull
                    wrote on sidst redigeret af
                    #82

                    Good info EL

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Stroka
                      wrote on sidst redigeret af
                      #83

                      God morgen 🙂

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #84

                        Norsk finanshus sænker Genmab til "sælg" https://www.proinvestor.com/investornyt/925657/norsk-finanshus-saenker-genmab-til-saelg

                        1 Reply Last reply
                        0
                        • J Offline
                          J Offline
                          JKY_VH
                          wrote on sidst redigeret af
                          #85

                          Fred være med det og god morgen;-)

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            bibob
                            wrote on sidst redigeret af
                            #86

                            God morgen. 🙂

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #87

                              DARA in refractory autoimmune conditions https://twitter.com/nikolasruffer/status/1612940755194073089

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #88

                                https://investors.abbvie.com/static-files/4d7aae8a-65ca-45f9-bc0f-a169b5a7dc9d
                                AbbVie JPM presentation

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Stockwatch1
                                  wrote on sidst redigeret af
                                  #89

                                  DNB: We expect focus in 2023 to be on epcoritamab’s approval,
                                  launch and initial uptake, but believe consensus is
                                  overestimating the latter while underestimating costs. In
                                  other words, in our view, we are not looking at a Darzalexlike launch curve. We see a risk of the 2023 guidance
                                  disappointing consensus

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Stockwatch1
                                    wrote on sidst redigeret af
                                    #90

                                    DNB: we have cut our target price
                                    DKK2,750 (2,982) and downgraded to SELL (HOLD)

                                    1 Reply Last reply
                                    0
                                    • V Offline
                                      V Offline
                                      Vitus
                                      wrote on sidst redigeret af
                                      #91

                                      DNB vil nok have nogle billige Genmab aktier….

                                      1 Reply Last reply
                                      0
                                      • V Offline
                                        V Offline
                                        Vitus
                                        wrote on sidst redigeret af
                                        #92

                                        Er det ikke useriøst ???

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gdn55
                                          wrote on sidst redigeret af
                                          #93

                                          Spåmanden fra DNB, har godt nok mange følgere, eller er det bare banken der selv leger.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper